NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 17:14இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Bliss GVS Pharma Secures UK MHRA Approval for Mesalazine 1g Suppositories
Bliss GVS Pharma Limited announced that its UK-based wholly owned subsidiary, Asterisk Lifesciences Ltd, has received Marketing Authorisation from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositories. The approval marks a key milestone in the company's strategy to expand into highly regulated western markets beyond its traditional semi-regulated African footprint (which historically drove ~93% of exports). Commercial launch timelines and targeted revenue potential were not disclosed in the filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுBliss GVS Pharma's wholly owned UK arm obtained formal regulatory marketing approval from the UK MHRA for Mesalazine 1g Suppositories.
ஏன் இது முக்கியம்It supports the company's stated strategic objective to diversify revenue away from African semi-regulated markets into high-margin, regulated European markets.
📅 குறுகிய காலம்Sentimentally positive as it validates the company's regulatory compliance and niche suppository formulation capabilities in a tier-1 regulated market.
📈 நீண்ட காலம்Structurally positive step towards lowering geographical concentration risks from Africa and scaling regulated market formulations.
⚠ அபாய எச்சரிக்கைகள்
Commercialization and pricing details not disclosed
Execution risk regarding distribution partnerships in the UK market
👀 கவனிக்க வேண்டியவை
Track management commentary in upcoming earnings calls regarding the UK commercial rollout timeline, distribution tie-ups, and market size addressable by this product.
Bliss GVS Issues Postal Ballot for Appointment of 3 Directors Following Promoter Change
Bliss GVS Pharma has issued a Postal Ballot Notice seeking shareholder approval for the appointment of three Non-Executive Non-Independent Directors: Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat. These appointments follow the completion of the Open Offer and the Share Purchase Agreement dated May 23, 2026, where Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited became the company's new promoters. Remote e-voting runs from October 16, 2026, to November 14, 2026, with results scheduled on or before November 17, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal initiation of shareholder voting to confirm three board nominees from the incoming promoter group (Anupam Rasayan / PAC).
ஏன் இது முக்கியம்Confirms governance transition and board reconstitution following the acquisition of control by Anupam Rasayan India Limited.
Directors proposed for appointment: 3Cut-off date: அக்டோபர் 09, 2026E-voting start date: அக்டோபர் 16, 2026E-voting end date: நவம்பர் 14, 2026Result declaration date: நவம்பர் 17, 2026
📅 குறுகிய காலம்Procedural compliance step; voting outcomes will formalize board composition without direct near-term financial impact.
📈 நீண்ட காலம்The entry of Anupam Rasayan nominees on the board solidifies the change in promoter control, which may drive new business strategy and governance standards over coming quarters.
⚠ அபாய எச்சரிக்கைகள்
Integration risks under new promoter management
Potential strategic shifts away from core legacy focus
👀 கவனிக்க வேண்டியவை
Track the e-voting results due on November 17, 2026, and look for management commentary on strategic integration or operational synergies with new promoter Anupam Rasayan.
Anupam Rasayan Takes Control of Bliss GVS Pharma; Promoters Reclassified
Bliss GVS Pharma confirmed that Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have acquired control of the company following an open offer and a Share Purchase Agreement dated May 23, 2026. The transaction was consummated on September 28, 2026, leading to the reclassification of erstwhile promoters to the public category. Anupam Rasayan and its 13 affiliated entities now form the new promoter and promoter group. This completes a formal change of ownership and management control for the Rs 7,298 crore market cap company.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal transfer of control of Bliss GVS Pharma to Anupam Rasayan India Ltd and Mates Visa Consultancy Pvt Ltd, with erstwhile promoters moving to the public category.
ஏன் இது முக்கியம்Represents a complete ownership transition to a major specialty chemical player, potentially unlocking synergies in API integration, global reach, and corporate governance.
SPA Execution Date: மே 23, 2026Transaction Consummation Date: செப்டம்பர் 28, 2026New Promoter Entities Listed: 15Market Capitalization Context: Rs 7298 கோடி
📅 குறுகிய காலம்Market may react positively to the clear resolution and formalization of the control shift to Anupam Rasayan.
📈 நீண்ட காலம்Structural changes under the new promoter could accelerate Bliss GVS's expansion into regulated markets and enhance manufacturing efficiencies.
⚠ அபாய எச்சரிக்கைகள்
Integration risks between specialty chemical and pharmaceutical formulations businesses
High export exposure (93% of revenue) mainly concentrated in African markets
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly filings and investor presentations for post-acquisition strategic directions, board reconstitutions, and operational synergies with Anupam Rasayan.
Bliss GVS Approves ESOP Schemes for Up to 73.50 Lakh Shares (~6.91% Dilution) at Rs 10 Exercise Price
Bliss GVS Pharma's Board has approved two new stock option schemes: Senior Executive ESOP 2026 (up to 26,50,000 shares, ~2.49% of capital) and Employee ESOP 2026 (up to 47,00,000 shares, ~4.42% of capital). Together, these schemes cover up to 73,50,000 equity shares, representing an aggregate equity dilution of ~6.91% on a fully diluted basis. The exercise price has been fixed at a steep discount of INR 10 per share compared to the current market price of Rs 683.6. Both schemes require shareholder approval and feature a minimum vesting period of one year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved the implementation of two new employee stock option plans totaling up to 6.91% equity dilution, subject to shareholder approval.
ஏன் இது முக்கியம்A 6.91% potential dilution with an exercise price of INR 10 (versus market price of Rs 683.6) helps retain key talent but will lead to equity dilution and non-cash share-based compensation charges impacting future reported profits.
📅 குறுகிய காலம்Shareholders will vote on the proposed schemes via postal ballot or EGM; stock may see mild neutral-to-cautious reaction due to the deeply discounted exercise price and dilution scale.
📈 நீண்ட காலம்If tied to performance milestones, the ESOPs could align management incentives with company expansion goals, though EPS will face dilution as options vest and are exercised.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~6.91% on fully diluted share capital
P&L impact from share-based compensation expenses due to deeply discounted exercise price (INR 10 vs CMP Rs 683.6)
👀 கவனிக்க வேண்டியவை
Track the upcoming shareholder voting for approval of the ESOP schemes and subsequent disclosures regarding the grant schedule, vesting criteria, and employee benefit expense amortisation.
Control shifts to Anupam Rasayan PAC as outgoing promoters' 34.82% stake reclassified to public
Bliss GVS Pharma has announced the formal completion of its acquisition by Anupam Rasayan India Limited and its affiliate PAC (Mates Visa Consultancy). Following the consummation of the share purchase agreement and open offer, the erstwhile promoter group's holding dropped from 34.82% (3,71,30,124 shares) to 0.01% (8,100 shares). The board noted the formal reclassification of these 27 outgoing promoters to the 'public' category pursuant to SEBI Listing Regulations.
உச்சம் நம்பிக்கை
என்ன மாறியதுControl of Bliss GVS Pharma has formally transferred to Anupam Rasayan/PAC, and outgoing promoters holding 34.82% have been reclassified to public shareholders.
ஏன் இது முக்கியம்A complete change of promoter and control can lead to strategic shifts in capital allocation, therapeutic focus, and management execution for the ₹8,147 Cr company.
📅 குறுகிய காலம்Market will watch for reconstituted board members and incoming leadership announcements following the completion of the takeover.
📈 நீண்ட காலம்New ownership under Anupam Rasayan could accelerate expansion into regulated global pharma markets and influence future earnings trajectories.
⚠ அபாய எச்சரிக்கைகள்
Management transition risks
Strategic misalignment during post-acquisition integration
👀 கவனிக்க வேண்டியவை
Track subsequent disclosures on incoming management appointments, board reconstitution, and any operational synergies outlined by Anupam Rasayan.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Anupam Rasayan and PAC Acquire 47.95% Stake in Bliss GVS, Taking Control as Promoters
Anupam Rasayan India Limited along with PAC (Mates Visa Consultancy) has completed the acquisition of a 47.95% stake (5,09,86,264 shares) in Bliss GVS Pharma Limited, successfully taking control as the new Promoters effective September 28, 2026. Concurrently, Managing Director Mr. Narsimha Shibroor Kamath has resigned from the board. Three new Non-Executive Non-Independent Directors (Hetul Mehta, Amar Shah, and Pramod Kasat) have been appointed, subject to postal ballot approval. This completes the transaction under the Share Purchase Agreement dated May 23, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுControl of Bliss GVS Pharma has formally transferred to Anupam Rasayan India Limited and PAC with a 47.95% stake, accompanied by the resignation of the incumbent Managing Director.
ஏன் இது முக்கியம்A complete change in promoters and leadership brings strategic redirection, potential operational synergies with Anupam Rasayan, and changes to capital deployment.
Total shares acquired: 5,09,86,264Acquired equity stake: 47.95%Shares acquired under open offer: 1669Effective date of control change: செப்டம்பர் 28, 2026
📅 குறுகிய காலம்Market sentiment will reflect the official transition of ownership and the integration with Anupam Rasayan's governance framework.
📈 நீண்ட காலம்Structural transformation likely as the new promoter steers the company into newer therapeutic categories or expanded geographic markets beyond semi-regulated African regions.
⚠ அபாய எச்சரிக்கைகள்
Management transition disruption following the exit of the long-standing Managing Director
Integration risks between specialty chemical and pharmaceutical formulation operating models
👀 கவனிக்க வேண்டியவை
Track the outcome of the upcoming postal ballot for board appointments and watch for strategic updates from the new promoters regarding synergies, governance, and capital allocation.
Only 1,669 Shares Tendered in Anupam Rasayan's ₹299/Share Open Offer for Bliss GVS
SBI Capital Markets issued the post-offer report regarding Anupam Rasayan India Ltd's (with PAC Mates Visa Consultancy) open offer for up to 2.77 crore shares (26.00% voting capital) of Bliss GVS Pharma at ₹299.00 per share. Due to prevailing market prices trading significantly above the offer price (current market price ~₹648.6), public participation was negligible, with only 1,669 equity shares tendered and accepted for a total consideration of ₹4,99,031. Under the underlying Share Purchase Agreement (SPA), the acquirer group is set to acquire a baseline of 4,58,03,024 shares (42.95% of voting capital) plus call options for an additional 4.88%, formalizing a change in control.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal closure and settlement of the mandatory open offer triggered by Anupam Rasayan / PAC acquiring controlling stake in Bliss GVS Pharma.
ஏன் இது முக்கியம்Confirms negligible public tendering due to the wide gap between the offer price (₹299) and market price, ensuring public float remains intact at 52.18% as ownership transitions via the SPA.
Open Offer Price: ₹ 299.00 per shareShares Offered (Max): 2,77,26,848 (26.00%)Shares Accepted: 1,669 (0.00%)SPA Base Acquisition: 4,58,03,024 shares (42.95%)Total Consideration Paid in Open Offer: ₹4,99,031
📅 குறுகிய காலம்Neutral to procedural; the negligible tendering was widely anticipated given market price levels. Trading will remain focused on operational performance.
📈 நீண்ட காலம்Strategic direction will be guided by Anupam Rasayan's control over Bliss GVS, potentially driving synergies across chemical synthesis, formulations, and regulated market expansion.
⚠ அபாய எச்சரிக்கைகள்
Integration and strategic alignment risks under new promoter/management control
High baseline geographical concentration in export markets (Africa)
👀 கவனிக்க வேண்டியவை
Track the formal completion/closing of the Share Purchase Agreement (SPA) and subsequent reconstitution of the board and management integration under Anupam Rasayan.
Bliss GVS Q1 PAT Rises 16% YoY to ₹51.4 Cr; Revenue Surges 38% to ₹285.6 Cr
Bliss GVS Pharma reported a strong start to FY27 with consolidated revenue growing 37.6% YoY to ₹285.58 Cr. Net profit increased 15.8% YoY to ₹51.37 Cr, while showing a significant 38.9% sequential jump from the preceding quarter (Q4 FY26). The company also announced the appointment of Mr. Santosh Parab as a Non-Executive Director and allotted 2.67 lakh shares under its ESOP scheme. The results reflect a robust run-rate, with Q1 revenue representing approximately 30.8% of the TTM revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுBliss GVS has reported its Q1 FY27 financial results, showing significant top-line and bottom-line growth compared to both YoY and QoQ periods, alongside a board-level appointment.
ஏன் இது முக்கியம்The strong performance validates the company's strategy of expanding into regulated markets and strengthening its African presence, potentially leading to a valuation re-rating if this growth trajectory persists.
Consolidated Revenue (Q1 FY27): ₹285.58 கோடிConsolidated PAT (Q1 FY27): ₹51.37 கோடிQ1 வருவாய் vs TTM வருவாய்: 30.8%YoY Revenue Growth: 37.6%QoQ PAT Growth: 38.9%ESOP Allotment: 2,67,250 பங்குகள்
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the strong sequential and yearly growth in earnings and revenue, which exceeded the previous quarter's performance.
📈 நீண்ட காலம்Structural growth is driven by the company's leadership in niche dosage forms like suppositories and its expansion from semi-regulated African markets into highly regulated global markets.
⚠ அபாய எச்சரிக்கைகள்
High geographic concentration with 93% of revenue tied to exports, mainly to Africa
Forex volatility risks due to high export exposure
Potential regulatory changes in Sub-Saharan African countries
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the 37%+ revenue growth in upcoming quarters and the impact of the Kenyan subsidiary (Theralife Pharma) on consolidated margins. Watch for shareholder approval of the new director appointment via the postal ballot.
₹299 Open Offer for 26% Stake in Bliss GVS Pharma by Anupam Rasayan
Anupam Rasayan India Limited has launched an open offer to acquire up to 26% (2.77 crore shares) of Bliss GVS Pharma at ₹299 per share, following a deal to acquire a 43.11% controlling stake. The Committee of Independent Directors (IDC) has reviewed the offer and deemed the ₹299 price fair under SEBI regulatory frameworks as it matches the negotiated purchase price. However, the IDC explicitly noted that the current market price (₹483.50 as of July 17, 2026) is significantly higher than the offer price, suggesting the offer is currently 'out of the money' for retail investors. This transaction marks a major change in control for the company, which has a market cap of ₹5,171 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnupam Rasayan is taking over as the new promoter/controller of Bliss GVS Pharma, triggering a mandatory open offer for public shareholders.
ஏன் இது முக்கியம்This represents a significant consolidation where a specialty chemical major (Anupam Rasayan) acquires a formulations leader in niche dosage forms (suppositories/pessaries), potentially leading to R&D and operational synergies.
📅 குறுகிய காலம்The stock may see volatility as the market absorbs the change in control; however, the open offer is unlikely to be fully subscribed by retail investors given the steep discount to the current market price.
📈 நீண்ட காலம்The entry of Anupam Rasayan as a promoter could provide Bliss GVS with better access to capital and technical expertise to expand into regulated markets, moving beyond its 93% export concentration in Africa.
⚠ அபாய எச்சரிக்கைகள்
Management transition risk
High geographic concentration (93% revenue from Africa)
Offer price is significantly below current market valuation
👀 கவனிக்க வேண்டியவை
Investors should monitor the market price relative to the ₹299 offer price; tendering shares is currently unattractive as the market price is substantially higher. Watch for the completion of the 43.11% stake transfer and subsequent changes in board composition or strategic direction under Anupam Rasayan's leadership.
26% Open Offer for Bliss GVS Pharma: Anupam Rasayan Adds PAC to Acquisition Bid
Anupam Rasayan India Limited is proceeding with a formal open offer to acquire up to 2,77,26,848 equity shares, representing 26.00% of Bliss GVS Pharma's expanded voting capital. This latest update adds Mates Visa Consultancy Private Limited as a Person Acting in Concert (PAC) with the acquirer. Given the current promoter holding is relatively low at 35.36%, this 26% offer is highly material and could lead to a significant change in the company's control or strategic direction. The company currently has a market capitalization of ₹5,347 Cr and TTM revenue of ₹927 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுAn additional entity, Mates Visa Consultancy Private Limited, has been officially joined as a PAC to Anupam Rasayan's existing open offer for Bliss GVS Pharma.
ஏன் இது முக்கியம்This signifies progress in a major acquisition attempt by a large specialty chemical player (Anupam Rasayan), which could provide Bliss GVS with better access to regulated markets and capital for its 20% targeted growth rate.
Open Offer Size (Shares): 2,77,26,848Open Offer Stake: 26.00%Current Promoter Holding: 35.36%TTM வருவாய்: ₹927 கோடிசந்தை மதிப்பு: ₹5,347 கோடி
📅 குறுகிய காலம்The stock is likely to remain volatile and trade near the anticipated open offer price as the market assesses the likelihood of a successful takeover.
📈 நீண்ட காலம்If successful, the entry of a strategic acquirer like Anupam Rasayan could re-rate the business by diversifying its geographic risk away from the current 93% African market concentration.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval hurdles
Offer price may be lower than current market price
Execution risk of the acquisition
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the upcoming Letter of Offer (LoF) for the specific 'Offer Price' per share. Compare the offer price against the current market price of ₹483.5 to determine the attractiveness of tendering shares.
Bliss GVS Appoints Rahul Adakmol as CEO; Narsimha Kamath to Continue as Managing Director
Bliss GVS Pharma has announced a leadership transition where Mr. Rahul Adakmol will take over as CEO effective July 15, 2026. The outgoing CEO, Mr. Narsimha Shibroor Kamath, will step down on July 14, 2026, but will continue to serve as the Managing Director, ensuring leadership continuity. Additionally, Mr. Santosh Parab, a Chartered Accountant with 35 years of experience, has been appointed as a Non-Executive Director. This move brings in a CEO with specialized experience in global market expansion across 70+ countries, aligning with the company's strategy to move into highly regulated markets.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has split the MD and CEO roles, appointing a professional CEO with global experience while the existing leader remains as Managing Director.
ஏன் இது முக்கியம்Professionalizing the leadership team is critical for Bliss GVS as it seeks to diversify its revenue base away from geographic concentration in Africa and enter highly regulated global markets.
New CEO Experience: 22+ yearsNew Director Experience: 35+ yearsTTM வருவாய்: ₹927 கோடிசந்தை மதிப்பு: ₹5,762 கோடிExport Revenue Concentration: 93%
📅 குறுகிய காலம்The market is likely to view the transition positively due to the retention of the current MD for continuity and the high-caliber profile of the incoming CEO.
📈 நீண்ட காலம்The appointment of a CEO with experience in 70+ countries is structurally significant for the company's goal to transition from semi-regulated to highly regulated pharmaceutical markets.
⚠ அபாய எச்சரிக்கைகள்
Execution risk during leadership transition
High geographic concentration in African markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the company's expansion into regulated markets under the new CEO, as the company currently derives 93% of its revenue from exports, primarily to Africa.
Bliss GVS Pharma Sets July 8, 2026, as Record Date for Final Dividend
Bliss GVS Pharma Limited has fixed July 8, 2026, as the record date to determine shareholder eligibility for the final dividend of FY 2025-26. The company's 41st Annual General Meeting (AGM) is scheduled for July 15, 2026, where the dividend will be put for shareholder approval. If approved, the dividend will be distributed to eligible shareholders on or before August 14, 2026. The share transfer books will remain closed from July 9 to July 15, 2026.
முக்கிய அம்சங்கள்
Record date for final dividend eligibility is Wednesday, July 8, 2026.41st Annual General Meeting (AGM) to be held on Wednesday, July 15, 2026.Book closure period set from July 9, 2026, to July 15, 2026, inclusive.Final dividend payment to be completed on or before August 14, 2026, subject to approval.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible. Monitor the AGM outcomes for management's outlook on the pharmaceutical business for the upcoming fiscal year.
Bliss GVS Pharma Declares 100% Final Dividend; 41st AGM Scheduled for July 15, 2026
Bliss GVS Pharma Limited has announced its 41st Annual General Meeting (AGM) for July 15, 2026, to approve the audited financial statements for FY 2025-26. The Board has recommended a final dividend of ₹1.00 per equity share (100% of face value), with July 08, 2026, set as the record date for eligibility. Shareholders will also vote on the re-appointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO. If approved, the dividend will be paid to eligible members on or before August 14, 2026.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹1.00 per equity share (100% on face value of ₹1) for FY 2025-26.Record date for determining dividend entitlement is fixed as Wednesday, July 08, 2026.The 41st AGM is scheduled for July 15, 2026, at 11:00 AM IST via Video Conferencing.Dividend payment, if approved, will be completed by August 14, 2026.Proposal for the re-appointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must ensure they hold the stock before the record date of July 08, 2026. Shareholders should also review the Annual Report for FY 2025-26 to assess the company's performance and growth outlook.
Bliss GVS Pharma Recommends Re. 1 Dividend; Sets July 8 as Record Date for TDS Purposes
Bliss GVS Pharma has recommended a final dividend of Re. 1.00 per equity share (100% of face value) for the financial year ended March 31, 2026. The company has fixed July 08, 2026, as the record date to determine shareholder eligibility for the payout. This communication outlines the Tax Deduction at Source (TDS) procedures, where a standard 10% tax applies to residents with a valid PAN, while a higher 20% rate applies to those with invalid or unlinked PANs. The dividend is subject to approval at the 41st Annual General Meeting scheduled for July 15, 2026.
முக்கிய அம்சங்கள்
Recommended final dividend of Re. 1.00 per equity share for FY 2025-2026.Record date for identifying eligible shareholders is fixed as Wednesday, July 08, 2026.TDS of 10% is applicable for resident shareholders with valid PAN; 20% for those without PAN or unlinked Aadhaar.Resident individuals are exempt from TDS if the total dividend amount does not exceed Rs. 10,000 during the tax year.Non-resident shareholders may avail beneficial DTAA rates by submitting required documentation by the July 8 deadline.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant before July 08, 2026. Those eligible for tax exemptions or lower withholding rates must submit the necessary forms (like Form 121) to the company's registrar by the cut-off date.
Anupam Rasayan to Acquire 26% Stake in Bliss GVS Pharma via Open Offer at ₹299 Per Share
Anupam Rasayan India Limited has filed a Draft Letter of Offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited, representing 26% of the expanded voting share capital. The cash offer is priced at ₹299.00 per share, providing a specific exit or entry valuation for public shareholders. The tendering period is tentatively scheduled to open on July 16, 2026, and close on July 29, 2026, following the initial public announcement made in May 2026.
முக்கிய அம்சங்கள்
Open offer for 2,77,26,848 equity shares representing 26.00% of the expanded voting share capital.Offer price set at ₹299.00 per equity share to be paid in cash.Acquirer identified as Anupam Rasayan India Limited; SBI Capital Markets is the Manager to the Offer.Tendering period scheduled from July 16, 2026, to July 29, 2026.Last date for communicating acceptance/rejection and completion of payment is August 12, 2026.
👀 கவனிக்க வேண்டியவை
Investors should compare the current market price of Bliss GVS Pharma against the offer price of ₹299; if the market price remains below this level, tendering shares in the open offer may be beneficial. Monitor for any upward revisions to the offer price or competing bids before the July 15 deadline.
Bliss GVS Pharma Limited has received an Inspection Closure Report from the World Health Organization (WHO), Geneva, for its manufacturing facility in Palghar, Maharashtra. The facility, located at Survey No. 43 & 44, Vevoor Village, is now confirmed to be in compliance with international WHO-Good Manufacturing Practices (GMP) standards. This certification validates the company's operational excellence and quality assurance protocols. Such compliance is often a prerequisite for participating in international procurement tenders and expanding global export footprints.
முக்கிய அம்சங்கள்
Manufacturing facility at Palghar (East), Maharashtra, receives official WHO-GMP compliance status.The certification follows an Inspection Closure Report issued by WHO, Geneva, Switzerland.Facility located at Survey No. 43 & 44, Vevoor Village, Palghar, meets international safety and quality standards.The compliance strengthens the company's position for global pharmaceutical exports and regulatory approvals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory milestone that enhances the company's credibility in international markets. Monitor for potential increases in export orders or new product launches from this certified facility.
Open Offer for Bliss GVS Pharma Limited via Detailed Public Statement
SBI Capital Markets Limited, acting as the Manager to the Open Offer, has submitted a Detailed Public Statement (DPS) for the acquisition of shares from public shareholders of Bliss GVS Pharma Limited. The offer is being made in accordance with Regulations 3(1) and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This process provides an exit opportunity for existing public shareholders following a significant acquisition or change in control. Investors should monitor the specific offer price and the tendering period once the full schedule is finalized.
முக்கிய அம்சங்கள்
SBI Capital Markets Limited is the designated Manager to the Open Offer.The offer is triggered under SEBI (SAST) Regulations 3(1) and 4, indicating a substantial acquisition of shares or control.A Detailed Public Statement (DPS) has been officially submitted to the Stock Exchanges.The offer is specifically directed at the public shareholders of Bliss GVS Pharma Limited.Compliance is being maintained with Regulation 13(4) and 15(2) of the Takeover Regulations.
👀 கவனிக்க வேண்டியவை
Shareholders should carefully review the Detailed Public Statement to identify the Open Offer price and compare it with the current market price. It is advisable to wait for the Letter of Offer before deciding whether to tender shares or hold them based on the new acquirer's vision for the company.
Anupam Rasayan to Acquire 26% Stake in Bliss GVS Pharma via Open Offer
Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma, representing 26% of the expanded voting share capital. This move follows a Share Purchase Agreement (SPA) with existing promoters and specific non-promoter shareholders. The expanded voting share capital is estimated at 10,66,41,722 shares, which includes 8,52,750 vested ESOPs. This acquisition marks a significant change in the company's ownership structure and strategic direction.
முக்கிய அம்சங்கள்
Open offer for 2,77,26,848 shares representing 26.00% of the expanded voting share capital.Expanded voting share capital stands at 10,66,41,722 shares, accounting for 8.52 lakh ESOPs expected to vest by March 2027.Acquirer is Anupam Rasayan India Limited, a listed specialty chemical manufacturer with a market presence since 2003.The offer is triggered by an Underlying Transaction involving a Share Purchase Agreement with promoters and public sellers.SBI Capital Markets Limited is acting as the Manager to the Open Offer.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the final offer price once fully disclosed and consider the long-term synergy potential of Anupam Rasayan's entry. Existing shareholders may choose to tender shares during the 10-day window or hold for potential re-rating under new management.
Anupam Rasayan to Acquire 43.3% Stake in Bliss GVS Pharma at ₹299/Share; Triggers Open Offer
Anupam Rasayan India Limited has entered into a Share Purchase Agreement to acquire a 43.30% stake in Bliss GVS Pharma from its promoters and select public shareholders. The transaction is priced at ₹299 per share, totaling approximately ₹1,369.51 crore for the initial stake. This acquisition triggers a mandatory open offer for an additional 26% stake from public shareholders at the same price. Upon completion, Anupam Rasayan will assume management control and be classified as the new promoter of the company.
முக்கிய அம்சங்கள்
Anupam Rasayan to acquire 4,58,03,024 shares (43.30% stake) at a fixed price of ₹299 per share.Total initial consideration for the 43.30% stake is valued at ₹1,369.51 crore.Mandatory open offer triggered for up to 26% additional equity at ₹299 per share.Purchaser has call options to acquire an additional 4.90% stake and any residual shares held by sellers.The deal will result in a complete change of control and management to Anupam Rasayan India Limited.
👀 கவனிக்க வேண்டியவை
Investors should note the ₹299 offer price as a significant benchmark for the stock's valuation. The entry of a strategic player like Anupam Rasayan may lead to operational synergies and long-term value creation, making it a positive development for minority shareholders.
Bliss GVS Pharma has approved its audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. A significant highlight for shareholders is the recommendation of a 100% final dividend, which translates to ₹1 per equity share. The company also confirmed the expansion of its global operations through new subsidiaries in Kenya and the Democratic Republic of the Congo. Shareholders will vote on these proposals at the upcoming Annual General Meeting scheduled for July 15, 2026.
முக்கிய அம்சங்கள்
Recommended a final dividend of 100%, equivalent to ₹1 per equity share of face value ₹1.Approved audited financial results for the full year ended March 31, 2026, with an unmodified audit opinion.Expanded global footprint with new subsidiaries: Theralife Pharma Ltd (Kenya) and Theralife Pharma RDC (Congo).Re-appointed BDO India Services Private Limited as the Internal Auditor for the 2026-27 financial year.Scheduled the 41st Annual General Meeting for July 15, 2026, to be held via video conferencing.
👀 கவனிக்க வேண்டியவை
The 100% dividend payout reflects management's confidence in the company's cash position and profitability. Investors should review the consolidated performance to gauge the impact of the new African subsidiaries on overall margins.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
